News for BeyondSpring Inc. (BYSI)

In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rat

BeyondSpring (BYSI) presents promising Phase 2 results of their 303 Study at the 2025 ASCO, showing improved efficacy in metastatic NSCLC patients. The

**media[638998]**

Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD”‘1/L1 therapySEE

**media[578202]**

**media[578169]**

BeyondSpring Inc. (BYSI) experienced a significant stock price decline of 6.17%, now trading at $1.64 per share. The trading volume reached 2,289 shares, with a

Neutropenia treatment industry is projected to witness a CAGR of 4.1% during the period 2024-2032. This growth can be attributed to rising R&D efforts...

BeyondSpring Inc. (BYSI) experienced a notable stock price increase of 5.39%, reaching $2.54 per share. The trading volume was 20,920 shares, with a turnover ra

The stock of BeyondSpring Inc. (BYSI) displayed significant volatility, with its value surging by 7.27%. The stock is currently priced at $2.36 per share, featu

BeyondSpring reports safer NSCLC therapy option

Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant Improvement in Overall Survival, Progression...

BeyondSpring (BYSI) files prospectus for potential offering of up to 10 million ordinary shares. This is not an offer to sell securities.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...

FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global...

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

California-based NKGen Biotech, Inc. (NKGN), a clinical-stage biotechnology company is up over 59% in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly traded company.